

Sewanti Limaye¹, Chetan Madre¹, Anjali Parab¹, Shefali Jain¹, Abir Mazumder¹, Sharvari Pardikar¹, Shubham Dubey¹, Komal Kawale¹, Sonal Minde¹, Jeena John¹, Smita Debnath¹, Janani Sambath², Irene George², Pritam Kataria¹, Darshit Shah¹, Rajas Patel¹, Sunil Regmi¹, Darshana Patil², Prashant Kumar², Rajan Datar²

Sir H.N. Reliance Foundation Hospital & Medical Research Centre

Datar Cancer Genetics

Corresponding Author email address: limayesewanti@gmail.com

INTRODUCTION


Genomic profiling is increasingly central to precision treatment in advanced lung cancer, but its benefit depends on timely and sustained clinical implementation.

In routine practice, genomic testing may be a one-time event, with limited re-profiling at progression and loss of patients from the treatment pathway.

In our pre-navigation cohort (n=95), 47.4% were lost to follow-up despite 35% undergoing genomic testing, highlighting a gap between molecular profiling and sustained precision care.

PLNP was developed to bridge this gap through navigator-led genomic profiling, MTB integration, treatment coordination, and longitudinal re-profiling.

METHODS



DISCUSSION AND CONCLUSION

- PLNP bridged the gap between genomic testing and sustained clinical care, with loss to follow-up decreasing from 47.4% to 9.9%.
- MTB integration and treatment coordination translated genomic findings into clinical therapy, with 86.2% receiving NGS-directed treatment and 93% initiating treatment within 14 days of genomic reporting.
- Longitudinal navigation enabled continued precision care as tumour biology evolved, with 97/252 (38%) patients undergoing serial genomic re-profiling.
- PLNP was associated with longer PFS, with median PFS increasing from 3.5 to 11 months (3.1-fold) compared with the pre-navigation cohort.
- Collectively, these findings suggest that integrating genomic testing with navigation, molecular decision-making and longitudinal follow-up may be more impactful than genomic testing as a standalone intervention

CONCLUSION

PLNP transformed genomic profiling from a one-time test into a longitudinal precision care pathway, enabling timely treatment, sustained patient engagement and re-profiling at disease evolution.

This integrated model provides a practical framework for delivering precision oncology in real-world practice.

REFERENCES & ACKNOWLEDGEMENTS

Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the CAP/IASLC/AMP. *J Thorac Oncol.* 2018;13(3):323-358. doi:10.1016/j.jtho.2017.12.001.

Tsimberidou AM, Kahle M, Vo HH, et al. Molecular tumour boards—current and future considerations for precision oncology. *Nat Rev Clin Oncol.* 2023;20:843-863. doi:10.1038/s41571-023-00824-4.

Rodon J, Soria JC, Berger R, et al. Molecular tumor board-guided precision oncology: implementation and clinical utility.

Molecular tumor board precision N-of-One study. *Nat Commun.* 2020. — Demonstrated real-world use of tissue NGS, cfDNA and multidisciplinary molecular interpretation to identify matched treatment options


Jha P, Mishra R, Joshi A, et al. Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: a real-world experience. *J Liquid Biopsy.* 2025;8:100300. doi:10.1016/j.jlb.2025.100300.

Limaye S, Shreenivas A, Patil D, et al. Liquid biopsy—A pivotal test to help navigate clinical decisions at a precision center in India! *J Liq Biopsy.* 2025;9:100323. doi:10.1016/j.jlb.2025.100323


Anoop TM, Raj L, Nair P, et al. Utility and real-world clinical outcomes of next-generation sequencing in advanced non-small-cell lung cancer in the South Indian population. *Oncologist.* 2025;30(7):oyaf168. doi:10.1093/oncolo/oyaf168.

RESULTS


LOSS TO FOLLOW-UP BEFORE AND DURING PRECISION LUNG NAVIGATION




GENOMIC-TO-TREATMENT CASCADE IN THE PLNP COHORT



GENOMIC REPORT TO TREATMENT INITIATION



NAVIGATOR-LED PRECISION CARE WAS ASSOCIATED WITH LONGER PFS



Longitudinal Precision Oncology Journey After First NGS

